API Outsourcing is Mixed - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

API Outsourcing is Mixed
Contract manufacturers of APIs and intermediates report gains, but express caution.


Pharmaceutical Technology
Volume 33, Issue 3, pp. 14


Patricia Van Arnum
Reduced expectations sum up the mood of contract manufacturing organizations (CMOs) of active pharmaceutical ingredients (APIs) and intermediates, according to a recent survey by the Synthetic Organic Chemical Manufacturers Association (SOCMA). SOCMA, the US-based trade association representing custom and batch manufacturers, released the results of its annual business survey at InformEX, which was held in San Francisco in late January. SOCMA conducted the survey Nov. 13–Dec. 22, 2008.

Although a majority of respondents (62%) reported that their companies had an increase in sales in 2008, this level was down from 2007, when 76% reported an increase, and 2006, when 79% reported a gain. And for 2009, only 61% of companies expect to realize a sales increase.

CMOs also had a slight decline in capacity utilization for 2008, when the survey reported an average capacity utilization among respondents of 72.7%. This level compares with 76.2% in 2007 and 75.7% in 2006.

The outlook for contract API manufacturing is still positive, but expectations are lower. Seventy-five percent of respondents expect more projects to be outsourced during the next three years. This level is down from the 80% in 2007 that felt that outsourcing was going to increase near term, but up from the 70% in 2006 that projected an increase.

So what is the bottom line? Despite downward indications, a majority of CMOs still expect sales gains in 2009, a fortunate development given the uncertain economy and difficulties other industries face.

Patricia Van Arnum is a senior editor of Pharmaceutical Technology. Read Patricia’s blog posts atPharmTech Talk

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here